Clinical trial
Adjuvant High-Dose, Sequential Chemotherapy in Treating Patients With Resected…
NCT00002679 · Yale University, Other · Completed
Key facts
| NCT number | NCT00002679 |
|---|---|
| Title | Adjuvant High-Dose, Sequential Chemotherapy in Treating Patients With Resected Breast Cancer |
| Official title | Sequential Adjuvant Chemotherapy With Doxorubicin, Taxol, and Cyclophosphamide for Stage II or III Resectable Breast Cancer With Four or More Involved Axillary Lymph Nodes |
| Lead sponsor | Yale University, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Biological, Drug, Radiation |
| Interventions | filgrastim, cyclophosphamide, doxorubicin hydrochloride, paclitaxel, tamoxifen citrate, radiation therapy |
| Enrollment | 89 |
| Start date | Feb 1, 1994 |
| Primary completion | Jan 1, 2002 |
| Completion | Jan 1, 2002 |
| First posted | Feb 6, 2004 |
| Last update posted | Aug 26, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: